Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Phase 1

Recruiting

Conditions: Colorectal Cancer
Hematologic Malignancy
Rectum Cancer
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Chronic Lymphocytic Leukemia
Hodgkin Lymphoma
Non Hodgkin Lymphoma

Interventions: Drug: Vactosertib
Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Drug: IL-2
Drug: Natural Killer Cells

First Posted Date: 2022-06-01

Last Posted Date: 2024-11-29

Lead Sponsor: Jennifer Eva Selfridge, MD

Target Recruit Count: 12

Registration Number: NCT05400122

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

Phase 1

Recruiting

Conditions: Non Hodgkin Lymphoma

Interventions: Biological: UF-KURE19 CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2022-06-01

Last Posted Date: 2025-01-07

Lead Sponsor: Changchun Deng, MD

Target Recruit Count: 16

Registration Number: NCT05400109

Locations: 🇺🇸
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Head and Neck Cancer
Ovarian Cancer
Pancreatic Cancer
Non Small Cell Lung Cancer
Colorectal Cancer
GastroEsophageal Cancer
Breast Cancer

Interventions: Drug: FT536
Drug: Cyclophosphamide
Drug: Fludarabine
Combination Product: Avelumab
Drug: IL-2
Combination Product: Pembrolizumab
Combination Product: Trastuzumab
Combination Product: Cetuximab
Combination Product: Amivantamab
Combination Product: Nivolumab
Combination Product: Atezolizumab

First Posted Date: 2022-05-27

Last Posted Date: 2023-09-21

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 5

Registration Number: NCT05395052

Locations: 🇺🇸
Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸
UCLA Division of Hematology-Oncology, Los Angeles, California, United States

and more 2 locations

Natural Killer (NK) Cell Therapy for B-Cell Malignancies

Phase 1

Recruiting

Conditions: B-cell Lymphoma
B-cell Acute Lymphoblastic Leukemia

Interventions: Drug: QN-019a
Drug: Rituximab
Drug: Cyclophosphamid
Drug: Fludarabine
Drug: VP-16

First Posted Date: 2022-05-18

Last Posted Date: 2022-05-18

Lead Sponsor: Zhejiang University

Target Recruit Count: 24

Registration Number: NCT05379647

Locations: 🇨🇳
The First Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China

Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL

Phase 4

Recruiting

Conditions: Acute B Lymphoblastic Leukemia
Allogeneic Hematopoietic Stem Cell Transplantation

Interventions: Drug: Fludarabine

First Posted Date: 2022-05-18

Last Posted Date: 2022-05-18

Lead Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 142

Registration Number: NCT05379569

Locations: 🇨🇳
Shanghai General Hospital, Shanghai, China

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Phase 3

Recruiting

Conditions: Relapsed/Refractory Follicular Lymphoma

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Fludarabine
Drug: Rituximab
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Bendamustine

First Posted Date: 2022-05-12

Last Posted Date: 2024-12-24

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 230

Registration Number: NCT05371093

Locations: 🇪🇸
Hospital Universitari Vall d'Hebrón, Barcelona, Spain
🇪🇸
Hospital Clinic de Barcelona, Barcelona, Spain
🇪🇸
Instituto Catalan de Oncologia - Hospital Duran i Reynolds (ICO L'Hospitalet), Barcelona, Spain

and more 65 locations

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Phase 1

Recruiting

Conditions: Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Grade 3b Follicular Lymphoma
Refractory Grade 3b Follicular Lymphoma
Refractory Primary Mediastinal Large B-Cell Lymphoma
Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Lisocabtagene Maraleucel
Drug: Polymer-conjugated IL-15 Receptor Agonist NKTR-255
Procedure: X-Ray Imaging
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Lumbar Puncture
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Procedure: Biospecimen Collection
Procedure: Biopsy

First Posted Date: 2022-05-03

Last Posted Date: 2024-02-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 24

Registration Number: NCT05359211

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

HPV16 E6 TCR T Cells for Cervical Carcinoma

Phase 1

Recruiting

Conditions: Cervical Carcinoma

Interventions: Biological: TC-E202 cells
Drug: IL-2
Drug: Fludarabine
Drug: Cyclophosphamide Capsules

First Posted Date: 2022-05-02

Last Posted Date: 2024-04-12

Lead Sponsor: TCRCure Biopharma Ltd.

Target Recruit Count: 18

Registration Number: NCT05357027

Locations: 🇨🇳
Xiaochun Cheng, Chongqing, Chongqing, China

Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

Phase 1

Active, not recruiting

Conditions: Classical Hodgkin Lymphoma
Hodgkin Disease Refractory
Hodgkin Disease Recurrent

Interventions: Drug: Nivolumab
Drug: Autologous CD30.CAR-T
Drug: Fludarabine
Drug: Bendamustine

First Posted Date: 2022-04-29

Last Posted Date: 2023-04-03

Lead Sponsor: Tessa Therapeutics

Target Recruit Count: 15

Registration Number: NCT05352828

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸
University of Miami, Miami, Florida, United States

and more 2 locations

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Phase 1

Active, not recruiting

Conditions: Advanced Lung Non-Small Cell Carcinoma
Refractory Lung Non-Small Cell Carcinoma
Stage IIIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Metastatic Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Small Cell Carcinoma
Stage IVA Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8

Interventions: Biological: Antineoplastic Immune Cell
Biological: Atezolizumab
Procedure: Biospecimen Collection
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2022-04-19

Last Posted Date: 2024-05-29

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 6

Registration Number: NCT05334329

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy